Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Bevacizumab vs Gemcitabine, Cisplatin, and Placebo in Advanced Transitional Cell Carcinoma
NCT00942331Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Arm I (gemcitabine hydrochloride, cisplatin, placebo) with Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab) (2 arms). Primary endpoint: Overall Survival at 7 years. Started Jul 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT00942331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942331.